This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Preview: Chemours (CC) Q1 Earnings Expected to Decline
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours Provides Update in Response to Coronavirus Outbreak
by Zacks Equity Research
Chemours (CC) is likely to use the $300-million proceeds from borrowings in the future for working capital needs or other general corporate purposes.
Are Options Traders Betting on a Big Move in Chemours (CC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.
Here's Why You Should Hold Onto Chemours (CC) Stock Now
by Zacks Equity Research
Chemours (CC) should gain from its actions to drive Opteon adoption and boost productivity across its business segments in 2020.
Chemours (CC) Down 34.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours (CC) Inaugurates State-of-the-art Innovation Center
by Zacks Equity Research
Chemours' (CC) new facility is one of Delaware's biggest R&D centers and one of the largest R&D facilities in the chemical industry.
Chemours (CC) Earnings Beat, Revenues Miss Estimates in Q4
by Zacks Equity Research
Lower volumes and prices in Titanium Technologies and Fluoroproducts units hurt Chemours' (CC) Q4 sales.
Implied Volatility Surging for Chemours (CC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.
Chemours (CC) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Our proven model does not predict an earnings beat for Chemours (CC) this season.
Chemours' Opteon XP10 Refrigerants Chosen by Sharc Energy
by Zacks Equity Research
Chemours (CC) anticipates the collaboration to help Sharc Energy engage in refrigerant solutions that are more environmentally sustainable.
Implied Volatility Surging for Chemours (CC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.
Chemours (CC) Down 22.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is the Options Market Predicting a Spike in Chemours (CC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.
Chemours (CC) Earnings Top, Revenues Miss Estimates in Q3
by Zacks Equity Research
Illegal imports of HFC refrigerants and weaker demand for base refrigerants hurt Chemours' (CC) Fluoroproducts unit in Q3.
Chemours (CC) Beats Q3 Earnings Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 5.36% and -0.19%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Chemours (CC) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Our proven model does not conclusively predict that Chemours (CC) is likely to beat the Zacks Consensus Estimate this quarter.
Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours (CC) Down 22% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours' (CC) Earnings and Revenues Miss Estimates in Q2
by Zacks Equity Research
Weak demand for Ti-Pure TiO2 and Illegal imports of HFC refrigerants hurt Chemours (CC) in Q2.
Chemours (CC) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of -20.00% and -7.97%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Chemours (CC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Chemours (CC) is expected to see some pressure on Ti-Pure TiO2 volumes in Q2.
Earnings Preview: Chemours (CC) Q2 Earnings Expected to Decline
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours Inaugurates Opteon Facility, Boosts Production
by Zacks Equity Research
Chemours' (CC) new Texas-based facility will triple its production capacity of Opteon YF, which minimizes greenhouse gases.
Chemours (CC) Down 35% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours' Opteon Refrigerants Selected by MEHITS Applications
by Zacks Equity Research
Chemours' (CC) Opteon XL41 is an A2L class refrigerant that offers the lowest GWP replacement solution.